Home page  |  Help  |  Clear
English  |  French
 Search  |  Categories  |  Titles A-Z  |  Countries  |  Compare countries  |  Index  
Full TOC
Expand Document
Expand Chapter
Preferences

close this bookGuidelines to Antiretroviral Drug Therapy in Kenya (WHO; 2001; 78 pages)
View the documentFOREWORD
View the documentACKNOWLEDGMENT
Open this folder and view contentsCHAPTER ONE: INITIATING ANTIRETROVIRAL THERAPY
Open this folder and view contentsCHAPTER TWO: MONITORING AND CHANGING THERAPY
Open this folder and view contentsCHAPTER THREE: PHARMACOTHERAPEUTICS OF ARVS
close this folderCHAPTER FOUR: GUIDELINES FOR THE USE OF ANTIRETROVIRAL DRUGS IN PAEDIATRIC HIV INFECTION
View the document4.1 Overview
View the document4.2 Diagnosis of HIV infection in children
View the document4.3 When to initiate treatment
View the document4.4 Initiation of treatment
View the document4.5 Agents to choose for initial treatment
View the document4.6 Dosages for paediatric formulations
View the document4.8 Monitoring
View the document4.9 When to change therapy
Open this folder and view contentsCHAPTER FIVE: MANAGEMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTED PREGNANT WOMEN AND PREVENTION OF MOTHER TO CHILD TRANSMISSION (MTCT) OF HIV
Open this folder and view contentsCHAPTER SIX: SPECIAL CONSIDERATIONS
Open this folder and view contentsCHAPTER SEVEN: WHEN TO STOP TREATMENT (INTERRUPTIONS)
Open this folder and view contentsCHAPTER EIGHT: GUIDELINES FOR POST EXPOSURE PROPHYLAXIS
View the documentCHAPTER NINE: ACCESS TO DRUGS IN KENYA
Open this folder and view contentsAPPENDICES
View the documentBACK COVER
 

4.1 Overview

HIV infection in children is predominantly acquired perinatally and differs from disease in adults in its clinical presentation and disease progression.

There are marked age dependent differences in the profile of T lymphocyte subsets in children. In infancy, CD4 cell counts are generally higher than adult levels and attain adult levels by the age of 6 years. Unlike the absolute CD4 cell counts where the levels specifying immune suppression changes with age, the CD4 percentage specifying immune suppression does not change with age and is therefore a more useful marker for identifying disease progression in children. Infants with CD4 percentage of 15-25% are considered moderately immune suppressed and those with percentage CD4 levels < 15% are considered severely immune suppressed.

Regarding the use of viral load to guide therapy it is worth noting that perinatally infected infants have high plasma viral loads within the first 2 months of life. This is followed by a slow decline in the first few years of live. The level of HIV RNA considered indicative of increased risk for disease progression is not well defined for young children and will have to be reviewed as more data becomes available.

Treatment guidelines for children will therefore have to take these differences into account although they follow the same principles as in adults.

to previous sectionto next section

Please provide your feedback English  |  French